Sialic acid-binding lectin (leczyme) induces caspase-dependent apoptosis-mediated mitochondrial perturbation in Jurkat cells

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1402-1412

  Tatsuta, Takeo ^a   Hosono, Masahiro ^a   Sugawara, Shigeki ^a   Kariya, Yukiko ^b   Ogawa, Yukiko ^c   Hakomori, Senitiroh ^d   Nitta, Kazuo ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c Faculty of Pharmaceutical Sciences   (Japan)

^d PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

Antitumor effect; Caspase pathway; Lectin; Leczyme; Mitochondria perturbation; Rana catesbeiana; Ribonuclease

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; LECTIN; MULTIDRUG RESISTANCE PROTEIN; RIBONUCLEASE; SIALIC ACID BINDING LECTIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BULLFROG; BURKITT LYMPHOMA; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; DEPOLARIZATION; DNA DAMAGE; DNA FRAGMENTATION; ENZYME ACTIVITY; ERYTHROLEUKEMIA; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; T CELL LEUKEMIA;

AMPHIBIAN PROTEINS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; FLOW CYTOMETRY; HUMANS; JURKAT CELLS; LECTINS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEASES; RNA, MESSENGER;

EID: 84885044941     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2092     Document Type: Article

References (64)

1. Costanzi J, Sidransky D, Navon A and Goldsweig H: Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest 23: 643-650, 2005.
2. Deshpande RA and Shankar V: Ribonucleases from T2 family. Crit Rev Microbiol 28: 79-122, 2002.
3. Fang EF, Zhang CZ, Fong WP and Ng TB: RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways. Apoptosis 17: 377-387, 2012.
4. D'Alessio G: New and cryptic biological messages from RNases. Trends Cell Biol 3: 106-109, 1993.
5. Raines RT: Ribonuclease A. Chem Rev 98: 1045-1066, 1998.
6. Ita M, Halicka HD, Tanaka T, Kurose A, Ardelt B, Shogen K and Darzynkiewicz Z: Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines. Cancer Biol Ther 7: 1104-1108, 2008.
7. Rybak SM, Pearson JW, Fogler WE, Volker K, Spence SE, Newton DL, Mikulski SM, Ardelt W, Riggs CW, Kung HF and Longo DL: Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. J Natl Cancer Inst 88: 747-753, 1996.
8. Kim DH, Kim EJ, Kalota A, Gewirtz AM, Glickson J, Shogen K and Lee I: Possible mechanisms of improved radiation response by cytotoxic RNase, Onconase, on A549 human lung cancer xenografts of nude mice. Adv Exp Med Biol 599: 53-59, 2007.
9. Halicka HD, Murakami T, Papageorgio CN, Mittelman A, Mikulski SM, Shogen K and Darzynkiewicz Z: Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase. Cell Prolif 33: 407-417, 2000.
10. Tsai SY, Hsieh TC, Ardelt B, Darzynkiewicz Z and Wu JM: Combined effects of onconase and IFN-beta on proliferation, macromolecular syntheses and expression of STAT-1 in JCA-1 cancer cells. Int J Oncol 20: 891-896, 2002.
11. Mikulski SM, Viera A, Darzynkiewicz Z and Shogen K: Synergism between a novel amphibian oocyte ribonuclease And lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br J Cancer 66: 304-310, 1992.
12. Rutkoski TJ, Kink JA, Strong LE, Schilling CI and Raines RT: Antitumor activity of ribonuclease multimers created by site-specific covalent tethering. Bioconjug Chem 21: 1691-1702, 2010.
13. Haigis MC, Kurten EL and Raines RT: Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res 31: 1024-1032, 2003.
14. Ledoux L and Brachet J: Remarks on preparations of ribonuclease from different manufacturing sources. Biochim Biophys Acta 16: 290, 1955.
15. Ledoux L: Action of ribonuclease on neoplastic growth. II. Action on Landschutz ascites cells in vitro. Biochim Biophys Acta 20: 369-377, 1956.
16. Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ and Shogen K: Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet 21: 169-182, 1988.
17. Easty DM, Ledoux L and Ambrose EJ: The action of ribonuclease on neoplastic growth. III. Studies by interference microscopy. Biochim Biophys Acta 20: 528-537, 1956.
18. Telford IR, Kemp JF, Taylor EF and Yeaman MW: Effect of ribonuclease on survival of ascites tumor bearing mice. Proc Soc Exp Biol Med 100: 829-831, 1959.
19. Ledoux L: Action of ribonuclease on two solid tumours in vivo. Nature 176: 36-37, 1955.
20. Ardelt W, Mikulski SM and Shogen K: Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases. J Biol Chem 266: 245-251, 1991.
21. Ledoux L and Revell SH: Action of ribonuclease on neoplastic growth. I. Chemical aspects of normal tumour growth: the Landschutz ascites tumour. Biochim Biophys Acta 18: 416-426, 1955.
22. Aleksandrowicz J, Urbanczyk J, Ostrowska A and Sierko J: Further research on the activity of ribonucleases in the blood and urine of patients suffering from proliferative hemocytopathia. Blood 13: 652-664, 1958.
23. Vert A, Castro J, Ruiz-Martinez S, Tubert P, Escribano D, Ribo M, Vilanova M and Benito A: Generation of new cytotoxic human ribonuclease variants directed to the nucleus. Mol Pharm 9: 2894-2902, 2012.
24. Fang EF and Ng TB: Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochim Biophys Acta 1815: 65-74, 2011.
25. Castro J, Ribo M, Navarro S, Nogues MV, Vilanova M and Benito A: A human ribonuclease induces apoptosis associated with p21WAF1/CIP1 induction and JNK inactivation. BMC Cancer 11: 9, 2011.
26. Kawauchi H, Sakakibara F and Watanabe K: Agglutinins of frog eggs: a new class of proteins causing preferential agglutination of tumor cells. Experientia 31: 364-365, 1975.
27. Sakakibara F, Kawauchi H, Takayanagi G and Ise H: Egg lectin of Rana japonica and its receptor glycoprotein of Ehrlich tumor cells. Cancer Res 39: 1347-1352, 1979.
28. Nitta K, Takayanagi G, Kawauchi H and Hakomori S: Isolation and characterization of Rana catesbeiana lectin and demonstration of the lectin-binding glycoprotein of rodent and human tumor cell membranes. Cancer Res 47: 4877-4883, 1987.
29. Titani K, Takio K, Kuwada M, Nitta K, Sakakibara F, Kawauchi H, Takayanagi G and Hakomori S: Amino acid sequence of sialic acid binding lectin from frog (Rana catesbeiana) eggs. Biochemistry 26: 2189-2194, 1987.
30. Kamiya Y, Oyama F, Oyama R, Sakakibara F, Nitta K, Kawauchi H, Takayanagi Y and Titani K: Amino acid sequence of a lectin from Japanese frog (Rana japonica) eggs. J Biochem 108: 139-143, 1990.
31. Nitta K, Oyama F, Oyama R, Sekiguchi K, Kawauchi H, Takayanagi Y, Hakomori S and Titani K: Ribonuclease activity of sialic acid-binding lectin from Rana catesbeiana eggs. Glycobiology 3: 37-45, 1993.
32. Okabe Y, Katayama N, Iwama M, Watanabe H, Ohgi K, Irie M, Nitta K, Kawauchi H, Takayanagi Y, Oyama F, et al: Comparative base specificity, stability, and lectin activity of two lectins from eggs of Rana catesbeiana and R. japonica and liver ribonuclease from R. catesbeiana. J Biochem 109: 786-790, 1991.
33. Nitta K, Ozaki K, Ishikawa M, Furusawa S, Hosono M, Kawauchi H, Sasaki K, Takayanagi Y, Tsuiki S and Hakomori S: Inhibition of cell proliferation by Rana catesbeiana and Rana japonica lectins belonging to the ribonuclease superfamily. Cancer Res 54: 920-927, 1994.
34. Nitta K, Ozaki K, Tsukamoto Y, Furusawa S, Ohkubo Y, Takimoto H, Murata R, Hosono M, Hikichi N, Sasaki K, et al: Characterization of a Rana catesbeiana lectin-resistant mutant of leukemia P388 cells. Cancer Res 54: 928-934, 1994.
35. Nitta K, Ozaki K, Tsukamoto Y, Hosono M, Ogawakonno Y, Kawauchi H, Takayanagi Y, Tsuiki S and Hakomori S: Catalytic lectin (leczyme) from bullfrog (Rana catesbeiana) eggs. Int J Oncol 9: 19-23, 1996.
36. Liao YD: A pyrimidine-guanine sequence-specific ribonuclease from Rana catesbeiana (bullfrog) oocytes. Nucleic Acids Res 20: 1371-1377, 1992.
37. Liao YD, Huang HC, Leu YJ, Wei CW, Tang PC and Wang SC: Purification and cloning of cytotoxic ribonucleases from Rana catesbeiana (bullfrog). Nucleic Acids Res 28: 4097-4104, 2000.
38. Tang CH, Hu CC, Wei CW and Wang JJ: Synergism of Rana catesbeiana ribonuclease And IFN-gamma triggers distinct death machineries in different human cancer cells. FEBS Lett 579: 265-270, 2005.
39. Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y and Ueno K: A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 44: 1299-1305, 1997.
40. Liao YD, Huang HC, Chan HJ and Kuo SJ: Large-scale preparation of a ribonuclease from Rana catesbeiana (bullfrog) oocytes and characterization of its specific cytotoxic activity against tumor cells. Protein Expr Purif 7: 194-202, 1996.
41. Hu CC, Lee YH, Tang CH, Cheng JT and Wang JJ: Synergistic cytotoxicity of Rana catesbeiana ribonuclease And IFN-gamma on hepatoma cells. Biochem Biophys Res Commun 280: 1229-1236, 2001.
42. Thomas H and Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10: 159-165, 2003.
43. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I and Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398, 1999.
44. Krishna R and Mayer LD: Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11: 265-283, 2000.
45. Stavrovskaya AA: Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 65: 95-106, 2000.
46. Ozben T: Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 580: 2903-2909, 2006.
47. Castro J, Ribo M, Puig T, Colomer R, Vilanova M and Benito A: A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines. Invest New Drugs 30: 880-888, 2012.
48. Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol 35: 495-516, 2007.
49. Grutter MG: Caspases: key players in programmed cell death. Curr Opin Struct Biol 10: 649-655, 2000.
50. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB and Claret FX: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278: 19245-19256, 2003.
51. Bunyard P, Handley M, Pollara G, Rutault K, Wood I, Chaudry M, Alderman C, Foreman J, Katz DR and Chain BM: Ribotoxic stress activates p38 and JNK kinases and modulates the antigen-presenting activity of dendritic cells. Mol Immunol 39: 815-827, 2003.
52. He K, Zhou HR and Pestka JJ: Mechanisms for ribotoxin-induced ribosomal RNA cleavage. Toxicol Appl Pharmacol 265: 10-18, 2012.
53. Iordanov MS, Wong J, Newton DL, Rybak SM, Bright RK, Flavell RA, Davis RJ and Magun BE: Differential requirement for the stress-activated protein kinase/c-Jun NH(2)-terminal kinase in RNA damage-induced apoptosis in primary and in immortalized fibroblasts. Mol Cell Biol Res Commun 4: 122-128, 2000.
54. Fang EF, Zhang CZ, Zhang L, Fong WP and Ng TB: In vitro and in vivo anticarcinogenic effects of RNase MC2, a ribonuclease isolated from dietary bitter gourd, toward human liver cancer cells. Int J Biochem Cell Biol 44: 1351-1360, 2012.
55. Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P and Grant S: The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 115: 4478-4487, 2010.
56. Chen J, Rusnak M, Luedtke RR and Sidhu A: D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J Biol Chem 279: 39317-39330, 2004.
57. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G and Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004.
58. Wolf BB and Green DR: Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 274: 20049-20052, 1999.
59. Kuwana T, Smith JJ, Muzio M, Dixit V, Newmeyer DD and Kornbluth S: Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c. J Biol Chem 273: 16589-16594, 1998.
60. Li H, Zhu H, Xu CJ and Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998.
61. Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
62. Schendel SL, Azimov R, Pawlowski K, Godzik A, Kagan BL and Reed JC: Ion channel activity of the BH3 only Bcl-2 family member, BID. J Biol Chem 274: 21932-21936, 1999.
63. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730, 2001.
64. Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF and Andersen JK: Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced Parkinson's disease. J Neurosci 21: 9519-9528, 2001.